参考文献/References:
[1] Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA：Cancer J Clin,2016,66:730.
[2] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].Cancer J Clin,2016.
[3] Khorana AA,Francis CW,Culakova E,et al.Frequency,risk factors,and trends for venous thromboembolism among hospitalized cancer patients[J].Cancer,2007,113(1):23392346.
[4] Timp JF,Braekkan SK,Versteeg HH,et al.Epidemiology of cancerassociated venous thrombosis[J].Blood,2013,122(10):17121723.
[5] Marinho FC,Takagaki TY.Hypercoagulability and lung cancer[J].Jornal Brasileiro De Pneumologia Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia,2008,34(5):312322.
[6] Andrew M,Paes B,Milner R,et al.Development of the human coagulation system in the fullterm infant[J].Blood,1987,70(1):165.
[7] Kario K,Matsuo T.Lipidrelated hemostatic abnormalities in the elderly:imbalance between coagulation and fibrinolysis[J].Atherosclerosis,1993,103(2):131138.
[8] Kurachi K,Zhang K,Ameri A,et al.Genetic and molecular mechanisms of age regulation (homeostasis) of blood coagulation[J].Iubmb Life,2000,49(3):189.
[9] 韩仁强,郑荣寿,张思维,等.1989年2008年中国肺癌发病性别、城乡差异及平均年龄趋势分析[J].中国肺癌杂志,2013,16(9):445451.
[10] Lysov Z,Dwivedi DJ,Gould TJ,et al.Procoagulant effects of lung cancer chemotherapy:impact on microparticles and cellfree DNA[J].Blood Coagulation & Fibrinolysis An International Journal in Haemostasis & Thrombosis,2016：28.
[11] Hahn N,Heiden M,Seitz R,et al.Inducible expression of tissue factor in smallcell lung cancer:impact on morphology and matrix metalloproteinase secretion[J].Journal of Cancer Research and Clinical Oncology,2012,138(4):695.
[12] Levine M.Cancer Patients.In:Goldhaber SZ,editors.Preventionof venous thromboembolism[J].New York:Marcel Dekker,1993:463483.
[13] Huber O,Bounameaux H,Borst F,Rohner A.Postoperative pulmonaryembolism after hospital discharge.An underestimated risk[J].Arch Surg,1992,127:310313.
[14] Bergqvist D,Agnelli G,Cohen A T,et al.Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer[J].New England Journal of Medicine,2002,346(13):975980.
[15] Hallahan D,Chen AY,Teng M,Cmelac AJ.Drugradiation interactionsin tumor blood vessels[J].Oncology (Huntingt) 1999,13:7177.
[16] Prandoni P,Falanga A,Piccioli A.Cancer and venous thromboembolism[J].Lancet Oncology,2005,6(6):401410.
[17] Vignoli A,Marchetti M,Russo L,et al.LMWH bemiparin and ULMWH RO14 reduce the endothelial angiogenic features elicited by leukemia,lung cancer,or breast cancer cells[J].Cancer Investigation,2011:556558.
[18] Versteeg HH,Spek CA,Slofstra SH,et al.FVIIa:TF induces cell survival via G12/G13dependent Jak/STAT activation and BclXL production[J].Circulation Research,2004,94(8):1032.
[19] Amirkhosravi A,Meyer T,Amaya M,et al.The role of tissue factor pathway inhibitor in tumor growth and metastasis[J].Seminars in Thrombosis & Hemostasis,2007,33(7):643.
[20] Harvey J,Mellor PH,Lennard T,et al.Inhibition of CXCR4mediated breast cancer metastasis:a potential role for heparinoids?[J].Clinical Cancer Research,2007,13(5):15621570.
[21] Simka M.Antimetastatic activity of heparin is probably associated with modulation of SDF1CXCR4 axis.[J].Medical Hypotheses,2007,69(3):709.
[22] Prandoni P,Falanga A,Piccioli A.Cancer and venous thromboembolism[J].Lancet Oncol,2005,6(6):401410.
[23] Niers TM,Klerk CP,DiNisio M,Van Noorden CJ,Buller HR,Reitsma PH,et al.Mechanisms of heparin induced anticancer activity in experimental cancer models[J].Crit Rev Oncol Hematol,2007,61(3):195207.
[24] Phillips PG,Yalcin M,Cui H,et al.Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel nonanticoagulant low molecular weight heparin[J].Anticancer Research,2011.
[25] Lecumberri R,Lapez Vivanco G,Font A,et al.Adjuvant therapy with bemiparin in patients with limitedstage small cell lung cancer:results from the ABEL study[J].Thromb Res,2013,132:66670.
[26] Macbeth F,Noble S,Evans J,et al.Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer:FRAGMATIC Trial[J].J Clin Oncol 2016,34:488494.
[27] Macbeth F,Carte B,Noble S,et al.Further results of the FRAGMATIC trial of thromboprophylaxis in lung cancer[J].Transl Lung Cancer Res,2016,5:347349.
[28] 〖JP2〗Li XP.Clinical research on chemotherapy in combination with LMWH treatment of advanced lung cancer patients[J].Int J Clin Exp Med,2016,9(6):1141911428.〖JP〗
[29] Lebeau B,Baud M,Masanes M J,et al.Optimization of SmallCell Lung Cancer Chemotherapy with Heparin:A Comprehensive Retrospective Study of 239 Patients Treated in a Single Specialized Center[J].Chemotherapy,2011,57(3):253258.
[30] 〖JP2〗Altinbas M,Dikilitas M,Ozkan M,et al.The effect of smallmolecularweight heparin added to chemotherapy on survival in smallcell lung cancer A retrospective analysis.[J].Indian Journal of Cancer,2014,51(3):324329.〖JP〗
[31] pmhdev.Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and metaanalysis National Library of Medicine PubMed Health[J].Centre for Reviews & Dissemination,2013.
[32] 〖JP2〗王文萍,王垂杰.肿瘤转移的“痰毒流注”理论形成基础及实践意义[J].中国中医基础医学杂志,2002,8(5):46.〖JP〗
[33] 郁仁存,唐武军.平衡学说在肿瘤综合治疗中的应用[J].癌症进展,2004,2(6):438440.
[34] Wang X,Wang E,Kavanagh JJ,et al.Ovarian cancer,the coagulation pathway,and inflammation.J Transl Med 2005,3(1):25.
[35] Li C,Colman LM,Collier ME,et al.Tumourexpressed tissue factor inhibits cellular cytotoxicity.[J].Cancer Immunology Immunotherapy,2006,55(11):13011308.
[36] 〖JP2〗Yang F,Li J,Zhu J,et al.Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NFκB signaling pathway in H22 tumorbearing mice[J].Eur J Pharmacol,2015,754:105114.〖JP〗
[37] 〖JP2〗Zhang L,Ji Q,Liu X,et al.Norcantharidin inhibits tumor angiogenesis via blocking.VEGFR2/MEK/ERK signaling pathways[J].Cancer Sci,2013,104（5）:604610.〖JP〗
[38] 〖JP2〗Zhang JT,Fan YZ,Chen CQ,et al.Norcantharidin:a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo[J].Int J Oncol,2012,40（5）:15011514.〖JP〗
[39] 许振国,宋爱莉,殷玉琨,等.莪术油对大鼠乳腺癌癌前病变组织VEGF mRNA表达的影响[J].中华肿瘤防治杂志,2012,19(8):570574.
[40] 刘健翔,王 娟,蒋晓山,等.莪术醇诱导鼻咽癌CNE2细胞凋亡作用及其抗肿瘤机制探讨[J].时珍国医国药,2012,23(6):13391341.
[41] 夏荣龙,郑兰东,刘青光,等.肝癌致梗阻性黄疸时丹参对ICAM1表达的影响[J].第四军医大学学报,2005(13):12161218.
[42] 林洪生,李树奇,裴迎霞,等.川芎嗪、苦参碱对癌细胞与内皮细胞黏附及黏附因子表达的影响[J].中国新药杂志,1999,8(6):2628.
[43] 骆莹滨，吴建春，方志红，等.赤芍水提物对肺癌细胞的抑制效应研究[J].中国医药导报，2014，36（11）：21.
[44] 王力强,石华山,王永生.脂质体姜黄素在Lewis肺癌中的抗肿瘤和抗血管作用[J].四川大学学报:医学版,2013,44(1):4648.
[45] 杨紫翼,姜 毅.基于阴阳理论探析活血化瘀抗肿瘤转移之争议[J].国医论坛,2017,32(1):6263.
\[46\] 陈启亮,唐东昕,龙奉玺,等.浅析瘀血学说与肿瘤防治[J].贵阳中医学院学报,2016,38(5):14.
\[47\] 旋 静,连树林.肺癌的中医辨治[J].中国中医药现代远程教育,2015,13(11):78.
\[48\] 朱 盼,李泽庚.活血化瘀中药抗肺癌作用机制研究进展[J].亚太传统医药,2015,11(21):4749.
\[49\] 〖JP4〗田 菲,张军平,邢秀玲,等.活血化瘀法对肺癌合并肺感染患者免疫功能的影响[J].中国中医药科技,2011,18(1):89.〖JP〗
\[50\] 赵瑞宝,赵延龙,曹慧慧,等.大黄虫丸治疗肺癌机理浅析[J].中医药学报,2017,45(2):8283.
\[51\] 田建辉，刘海涛，刘嘉湘.畅达 “邪毒” 出路提高肿瘤疗效[J].中医杂志，2018，59(3):211214.
\[52\] 田建辉，刘海涛.通以治癌[J].上海中医药杂志，2018，52（8）:58.
相似文献/References:
[1]邵翠丽,周晋华△,杨勤军,等.周晋华运用环磷酰胺联合中药紫杉治疗晚期肺癌经验*[J].陕西中医,2020,(2):223.
SHAO Cuili,ZHOU Jinhua,YANG Qinjun,et al.ZHOU Jinhua treats advanced lung cancer with cyclophosphamide and purple shirt[J].,2020,(1):223.
[2]汪 莉,杜红旭,周正国,等.攻癌固真汤联合吉非替尼治疗肺癌气虚血瘀证疗效及对患者血流状态的影响[J].陕西中医,2021,(3):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
WANG Li,DU Hongxu,ZHOU Zhengguo,et al.Clinical effect of Gong'ai Guzhen decoction combined with gefitinib in treating lung cancer with Qixu Xueyu syndrome and affect blood flow state[J].,2021,(1):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
[3]郑 茜,刘远婷,丁甜甜,等.消积抑癌方对Lewis肺癌荷瘤小鼠MMP-2的影响[J].陕西中医,2021,(7):844.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
ZHENG Qian,LIU Yuanting,DING Tiantian,et al.Effect of Xiaoji Yi'ai recipe on MMP-2 in Lewis lung cancer bearing mice[J].,2021,(1):844.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
[4]刘文佳,刘宗凯,初晓苏,等.山慈菇-王不留行干预肺癌向骨转移过程生物信息学作用机制[J].陕西中医,2021,(9):1302.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.041]
[5]杨 昕,李和根.肺癌辨证分型研究进展[J].陕西中医,2021,(9):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
YANG Xin,LI Hegen.Progress in syndrome differentiation of lung cancer[J].,2021,(1):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
[6]李 健,贾 瑞,王 超,等.健脾益气汤联合化疗对肺癌术后患者免疫功能的影响[J].陕西中医,2023,(4):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
LI Jian,JIA Rui,WANG Chao,et al.Effect of Jianpi Yiqi decoction combined with chemotherapy on immune function in patients with lung cancer after surgery[J].,2023,(1):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
[7]宁永波,王雅兴,陈香颖,等.名中医王瑞平“期证相合”理论在肺癌术后研究肿瘤微环境经验[J].陕西中医,2023,(10):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
NING Yongbo,WANG Yaxing,CHEN Xiangying,et al.Wang Ruiping's theory of “phase correspondence” in postoperative lung cancer patients[J].,2023,(1):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
[8]张 尤,陈 炜.名中医韩明向基于“一本四证”论治肺癌经验[J].陕西中医,2023,(12):1788.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.027]
[9]陈香颖,宁永波,王雅兴,等.名中医王瑞平运用“培土生金法”治疗肺癌经验[J].陕西中医,2024,(4):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]
CHEN Xiangying,NING Yongbo,WANG Yaxing,et al.Experience of professor Wang Ruiping using “tonifying the spleen and replenishing the lung” to treat lung cancer[J].,2024,(1):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]
[10]王 倩,蒋思雨,刘倩希,等.加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效[J].陕西中医,2024,(8):1048.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.008]
WANG Qian,JIANG Siyu,LIU Qianxi,et al.Clinical efficacy of modified Maimendong decoction combined with anlotinib on advanced driver gene-negative non-small cell lung cancer[J].,2024,(1):1048.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.008]